Innova Captab Ltd
NSE:INNOVACAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
IN |
|
Enova International Inc
NYSE:ENVA
|
US |
|
C
|
Chemtech Industrial Valves Ltd
BSE:537326
|
IN |
|
Comstock Resources Inc
NYSE:CRK
|
US |
|
Kinovo PLC
LSE:KINO
|
UK |
Innova Captab Ltd
Innova Captab Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Panchkula, Haryana. The company went IPO on 2023-12-29. Innova Captab Ltd is an integrated pharmaceutical company. The firm is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. The company has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.
Innova Captab Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Panchkula, Haryana. The company went IPO on 2023-12-29. Innova Captab Ltd is an integrated pharmaceutical company. The firm is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. The company has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.
Revenue Growth: Innova Captab reported Q3 revenue of INR 450.3 crores, up 42.3% year-on-year, and 9M FY '26 revenue of INR 1,182.2 crores, up 27.3% YoY.
Profitability: EBITDA for Q3 was INR 71.1 crores (up 39.6% YoY) and 9M EBITDA stood at INR 183.7 crores (up 24.8% YoY), with margins stable around 15.5–15.8%.
Jammu Facility: Jammu contributed INR 89 crores in Q3 revenue, up from INR 60 crores in the previous quarter, is nearing EBITDA breakeven, and is expected to add to profits next year.
Branded Generics Surge: Q3 Branded Generics revenue was INR 151.6 crores, growing 79% YoY, driven by both domestic and international expansion.
Exports Rising: Exports made up 35% of Q3 revenue, up from 25–27% last year, reflecting growing global presence.
Guidance: Management expects overall 20% growth for FY '27, with Jammu facility targeted for INR 270–280 crores revenue this year.
